Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorOrigin Sciences

About this trial

The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.

The primary objective of the study is to assess whether significant changes in DNA mutation and methylation associated with Non-colorectal cancers of the Aero-digestive Tract (NCRCADT) can be detected in rectal mucus as shed cells and cell-free DNA (cfDNA) pass through the gut and theoretically can be collected from rectal mucus.

Secondary objectives will assess the participant acceptability of the OriCol™ Sampling Device for Pancreatic Ductal Adenocarcinoma, Non-Small Cell Cancer of the Lung, Colorectal Cancer and Urological Cancer controls as well as contributing to a genomic library collating information about rectal mucus.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Oricol Test

Treatment groups

450 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Origin Sciences

Lead sponsor

Royal Devon and Exeter NHS Foundation Trust

Collaborator

Norfolk and Norwich University Hospitals NHS Foundation Trust

Collaborator

The Leeds Teaching Hospitals NHS Trust

Collaborator